Make a presentation on acute pancreatitis management diagnosis and treatment
Asking for Preferences
Reading File
Searching PubMed
acute pancreatitis management guidelines
Finding Sources
Reading Article
PMID: 40651900
Reading Article
PMID: 38857482
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Loading Image
Loading Image
Running Command
mkdir -p /home/daytona/workspace/acute-pancreatitis-ppt && ls /home/daytona/work…
Writing File
~/acute-pancreatitis-ppt/index.html
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Acute Pancreatitis: Diagnosis & Management</title>
<style>
* { box-sizing: border-box; margin: 0; padding: 0; }
body { font-family: 'Segoe UI', Arial, sans-serif; background: #0d1b2a; color: #fff; overflow: hidden; }
/* Slide Container */
.slides-wrapper { width: 100vw; height: 100vh; position: relative; }
.slide {
display: none;
position: absolute; top: 0; left: 0;
width: 100%; height: 100%;
padding: 48px 60px;
flex-direction: column;
justify-content: flex-start;
}
.slide.active { display: flex; }
/* Navigation */
.nav {
position: fixed; bottom: 24px; left: 50%; transform: translateX(-50%);
display: flex; gap: 12px; align-items: center; z-index: 100;
background: rgba(0,0,0,0.5); padding: 10px 20px; border-radius: 30px;
backdrop-filter: blur(10px);
}
.nav button {
background: rgba(255,255,255,0.15); border: 1px solid rgba(255,255,255,0.3);
color: #fff; padding: 8px 20px; border-radius: 20px; cursor: pointer;
font-size: 14px; transition: all 0.2s;
}
.nav button:hover { background: rgba(255,255,255,0.3); }
.nav button:disabled { opacity: 0.3; cursor: default; }
.slide-counter { font-size: 13px; color: rgba(255,255,255,0.7); min-width: 70px; text-align: center; }
.progress-bar {
position: fixed; top: 0; left: 0; height: 3px; background: linear-gradient(90deg,#06b6d4,#3b82f6);
transition: width 0.3s; z-index: 100;
}
/* Keyboard hint */
.hint { position: fixed; top: 14px; right: 20px; font-size: 11px; color: rgba(255,255,255,0.35); }
/* ─── Slide Themes ─── */
/* Title slide */
.slide-title {
background: linear-gradient(135deg, #0f2444 0%, #1a3a5c 50%, #0d2d46 100%);
justify-content: center; align-items: center; text-align: center;
}
.slide-title .main-title { font-size: 52px; font-weight: 700; line-height: 1.2; margin-bottom: 16px;
background: linear-gradient(135deg,#67e8f9,#60a5fa,#a78bfa); -webkit-background-clip: text; -webkit-text-fill-color: transparent; }
.slide-title .subtitle { font-size: 22px; color: rgba(255,255,255,0.75); margin-bottom: 8px; }
.slide-title .meta { font-size: 15px; color: rgba(255,255,255,0.45); margin-top: 24px; }
.slide-title .badge {
display: inline-block; background: rgba(99,102,241,0.25); border: 1px solid rgba(99,102,241,0.5);
padding: 6px 18px; border-radius: 20px; font-size: 13px; color: #a5b4fc; margin-top: 20px;
}
/* Section header */
.slide-section {
background: linear-gradient(135deg, #1e1b4b 0%, #312e81 100%);
justify-content: center; align-items: flex-start;
}
.section-number { font-size: 80px; font-weight: 800; color: rgba(255,255,255,0.08); line-height: 1; margin-bottom: -20px; }
.section-title { font-size: 42px; font-weight: 700; color: #e0e7ff; margin-bottom: 12px; }
.section-subtitle { font-size: 18px; color: rgba(199,210,254,0.7); }
.section-icon { font-size: 56px; margin-bottom: 16px; }
/* Content slides */
.slide-content { background: linear-gradient(160deg, #0f172a 0%, #1e293b 100%); }
.slide-content2 { background: linear-gradient(160deg, #0c1a0f 0%, #14261a 100%); }
.slide-content3 { background: linear-gradient(160deg, #1a0f0f 0%, #2d1515 100%); }
.slide-content4 { background: linear-gradient(160deg, #0f0a1a 0%, #1e1533 100%); }
.slide-content5 { background: linear-gradient(160deg, #0a1520 0%, #102030 100%); }
/* Slide heading */
.slide-heading {
font-size: 28px; font-weight: 700; margin-bottom: 28px; padding-bottom: 12px;
border-bottom: 2px solid; display: flex; align-items: center; gap: 12px;
}
.slide-heading.blue { border-color: #3b82f6; color: #93c5fd; }
.slide-heading.green { border-color: #22c55e; color: #86efac; }
.slide-heading.red { border-color: #ef4444; color: #fca5a5; }
.slide-heading.purple { border-color: #a855f7; color: #d8b4fe; }
.slide-heading.cyan { border-color: #06b6d4; color: #67e8f9; }
.slide-heading.orange { border-color: #f97316; color: #fdba74; }
.slide-heading.yellow { border-color: #eab308; color: #fde047; }
/* Cards grid */
.card-grid { display: grid; gap: 16px; height: calc(100% - 80px); }
.card-grid-2 { grid-template-columns: 1fr 1fr; }
.card-grid-3 { grid-template-columns: 1fr 1fr 1fr; }
.card-grid-4 { grid-template-columns: 1fr 1fr 1fr 1fr; }
.card {
background: rgba(255,255,255,0.05); border: 1px solid rgba(255,255,255,0.1);
border-radius: 12px; padding: 20px; position: relative; overflow: hidden;
}
.card::before { content: ''; position: absolute; top: 0; left: 0; right: 0; height: 3px; }
.card.blue::before { background: linear-gradient(90deg,#3b82f6,#60a5fa); }
.card.green::before { background: linear-gradient(90deg,#22c55e,#86efac); }
.card.red::before { background: linear-gradient(90deg,#ef4444,#fca5a5); }
.card.purple::before { background: linear-gradient(90deg,#a855f7,#d8b4fe); }
.card.cyan::before { background: linear-gradient(90deg,#06b6d4,#67e8f9); }
.card.orange::before { background: linear-gradient(90deg,#f97316,#fdba74); }
.card.yellow::before { background: linear-gradient(90deg,#eab308,#fde047); }
.card.pink::before { background: linear-gradient(90deg,#ec4899,#f9a8d4); }
.card-title { font-size: 14px; font-weight: 700; text-transform: uppercase; letter-spacing: 0.05em; margin-bottom: 10px; opacity: 0.9; }
.card-title.blue { color: #60a5fa; }
.card-title.green { color: #86efac; }
.card-title.red { color: #fca5a5; }
.card-title.purple { color: #d8b4fe; }
.card-title.cyan { color: #67e8f9; }
.card-title.orange { color: #fdba74; }
.card-title.yellow { color: #fde047; }
.card-title.pink { color: #f9a8d4; }
/* Lists */
ul.styled { list-style: none; padding: 0; }
ul.styled li { padding: 5px 0 5px 22px; position: relative; font-size: 14px; line-height: 1.5; color: rgba(255,255,255,0.85); }
ul.styled li::before { content: '▸'; position: absolute; left: 0; color: #60a5fa; font-size: 12px; top: 6px; }
ul.styled.green li::before { color: #86efac; }
ul.styled.red li::before { color: #fca5a5; }
ul.styled.purple li::before { color: #d8b4fe; }
ul.styled.cyan li::before { color: #67e8f9; }
ul.styled.orange li::before { color: #fdba74; }
ul.styled.yellow li::before { color: #fde047; }
/* Badges / pills */
.pill {
display: inline-block; padding: 3px 10px; border-radius: 12px; font-size: 12px;
font-weight: 600; margin: 2px;
}
.pill.green { background: rgba(34,197,94,0.2); color: #86efac; border: 1px solid rgba(34,197,94,0.3); }
.pill.red { background: rgba(239,68,68,0.2); color: #fca5a5; border: 1px solid rgba(239,68,68,0.3); }
.pill.blue { background: rgba(59,130,246,0.2); color: #93c5fd; border: 1px solid rgba(59,130,246,0.3); }
.pill.yellow { background: rgba(234,179,8,0.2); color: #fde047; border: 1px solid rgba(234,179,8,0.3); }
.pill.purple { background: rgba(168,85,247,0.2); color: #d8b4fe; border: 1px solid rgba(168,85,247,0.3); }
.pill.orange { background: rgba(249,115,22,0.2); color: #fdba74; border: 1px solid rgba(249,115,22,0.3); }
.pill.cyan { background: rgba(6,182,212,0.2); color: #67e8f9; border: 1px solid rgba(6,182,212,0.3); }
/* Severity table */
.sev-table { width: 100%; border-collapse: collapse; font-size: 14px; }
.sev-table th { background: rgba(255,255,255,0.1); padding: 10px 14px; text-align: left; font-size: 12px; text-transform: uppercase; letter-spacing: 0.05em; color: rgba(255,255,255,0.6); }
.sev-table td { padding: 10px 14px; border-bottom: 1px solid rgba(255,255,255,0.07); color: rgba(255,255,255,0.85); vertical-align: top; }
.sev-table tr:hover td { background: rgba(255,255,255,0.04); }
/* Step-up approach */
.step { display: flex; align-items: flex-start; gap: 16px; margin-bottom: 14px; }
.step-num { min-width: 34px; height: 34px; border-radius: 50%; display: flex; align-items: center; justify-content: center; font-weight: 700; font-size: 15px; flex-shrink: 0; margin-top: 2px; }
.step-body { flex: 1; }
.step-title { font-size: 15px; font-weight: 700; margin-bottom: 4px; }
.step-desc { font-size: 13px; color: rgba(255,255,255,0.65); line-height: 1.4; }
/* Two-column layout */
.two-col { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; flex: 1; }
.three-col { display: grid; grid-template-columns: 1fr 1fr 1fr; gap: 16px; flex: 1; }
/* Image slide */
.img-panel { border-radius: 12px; overflow: hidden; border: 1px solid rgba(255,255,255,0.15); }
.img-panel img { width: 100%; height: 100%; object-fit: contain; background: #000; }
/* Alert box */
.alert {
padding: 12px 16px; border-radius: 8px; margin-bottom: 14px;
display: flex; align-items: flex-start; gap: 10px; font-size: 13px; line-height: 1.4;
}
.alert.warning { background: rgba(234,179,8,0.12); border: 1px solid rgba(234,179,8,0.3); color: #fde047; }
.alert.danger { background: rgba(239,68,68,0.12); border: 1px solid rgba(239,68,68,0.3); color: #fca5a5; }
.alert.info { background: rgba(59,130,246,0.12); border: 1px solid rgba(59,130,246,0.3); color: #93c5fd; }
.alert.success { background: rgba(34,197,94,0.12); border: 1px solid rgba(34,197,94,0.3); color: #86efac; }
.alert-icon { font-size: 18px; flex-shrink: 0; }
/* Criteria list */
.criteria { display: flex; flex-wrap: wrap; gap: 8px; }
.crit-item {
background: rgba(255,255,255,0.06); border: 1px solid rgba(255,255,255,0.12);
border-radius: 8px; padding: 8px 12px; font-size: 13px; flex: 1; min-width: 120px;
}
.crit-item .crit-val { font-size: 11px; color: rgba(255,255,255,0.5); margin-top: 2px; }
/* Highlight number */
.big-num { font-size: 36px; font-weight: 800; line-height: 1; }
.big-num.blue { color: #60a5fa; }
.big-num.green { color: #86efac; }
.big-num.red { color: #fca5a5; }
.big-num.yellow { color: #fde047; }
/* Flowchart */
.flow { display: flex; flex-direction: column; gap: 0; align-items: flex-start; flex: 1; }
.flow-step {
background: rgba(255,255,255,0.06); border: 1px solid rgba(255,255,255,0.12);
border-radius: 10px; padding: 12px 18px; width: 100%; font-size: 13px;
position: relative;
}
.flow-arrow { text-align: center; font-size: 20px; color: rgba(255,255,255,0.3); padding: 3px 0; }
.flow-step strong { display: block; font-size: 14px; margin-bottom: 3px; }
/* TOC */
.toc-item { display: flex; align-items: center; gap: 14px; padding: 10px 0; border-bottom: 1px solid rgba(255,255,255,0.07); font-size: 15px; }
.toc-num { width: 28px; height: 28px; border-radius: 50%; display: flex; align-items: center; justify-content: center; font-size: 12px; font-weight: 700; flex-shrink: 0; }
/* References */
.ref-item { font-size: 12px; color: rgba(255,255,255,0.55); padding: 6px 0; border-bottom: 1px solid rgba(255,255,255,0.05); line-height: 1.4; }
.ref-item span { color: #93c5fd; }
/* Responsive text clamp */
.text-sm { font-size: 13px; line-height: 1.5; color: rgba(255,255,255,0.8); }
.text-xs { font-size: 12px; line-height: 1.4; color: rgba(255,255,255,0.65); }
em.highlight { color: #fde047; font-style: normal; font-weight: 600; }
.mb-2 { margin-bottom: 8px; }
.mb-3 { margin-bottom: 12px; }
.mb-4 { margin-bottom: 16px; }
.flex-1 { flex: 1; }
.overflow-auto { overflow-y: auto; }
</style>
</head>
<body>
<div class="progress-bar" id="progressBar"></div>
<div class="hint">← → Arrow keys to navigate</div>
<div class="slides-wrapper" id="slides">
<!-- ══════════════════════════════════════════════════
SLIDE 1 — TITLE
══════════════════════════════════════════════════ -->
<div class="slide slide-title active">
<div class="main-title">Acute Pancreatitis</div>
<div class="subtitle">Diagnosis, Severity Assessment & Management</div>
<div class="meta">Comprehensive Clinical Review for Residents & Clinicians</div>
<div class="badge">Updated with IAP/APA 2025 Guidelines • ACG 2024 Guidelines</div>
<div style="margin-top:40px; display:flex; gap:24px; justify-content:center; flex-wrap:wrap;">
<div style="text-align:center; padding:16px 24px; background:rgba(255,255,255,0.06); border-radius:12px; border:1px solid rgba(255,255,255,0.1);">
<div class="big-num blue">300,000</div>
<div style="font-size:12px; color:rgba(255,255,255,0.5); margin-top:4px;">US hospitalizations/year</div>
</div>
<div style="text-align:center; padding:16px 24px; background:rgba(255,255,255,0.06); border-radius:12px; border:1px solid rgba(255,255,255,0.1);">
<div class="big-num yellow">~5%</div>
<div style="font-size:12px; color:rgba(255,255,255,0.5); margin-top:4px;">Overall mortality</div>
</div>
<div style="text-align:center; padding:16px 24px; background:rgba(255,255,255,0.06); border-radius:12px; border:1px solid rgba(255,255,255,0.1);">
<div class="big-num red">36–50%</div>
<div style="font-size:12px; color:rgba(255,255,255,0.5); margin-top:4px;">Mortality in severe AP</div>
</div>
<div style="text-align:center; padding:16px 24px; background:rgba(255,255,255,0.06); border-radius:12px; border:1px solid rgba(255,255,255,0.1);">
<div class="big-num green">80%</div>
<div style="font-size:12px; color:rgba(255,255,255,0.5); margin-top:4px;">Mild, self-limiting cases</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 2 — TABLE OF CONTENTS
══════════════════════════════════════════════════ -->
<div class="slide slide-content">
<div class="slide-heading blue">📋 Contents</div>
<div class="two-col flex-1">
<div>
<div class="toc-item"><div class="toc-num" style="background:rgba(59,130,246,0.3);color:#93c5fd;">1</div> Definition & Epidemiology</div>
<div class="toc-item"><div class="toc-num" style="background:rgba(99,102,241,0.3);color:#a5b4fc;">2</div> Etiology & Risk Factors</div>
<div class="toc-item"><div class="toc-num" style="background:rgba(168,85,247,0.3);color:#d8b4fe;">3</div> Pathogenesis</div>
<div class="toc-item"><div class="toc-num" style="background:rgba(236,72,153,0.3);color:#f9a8d4;">4</div> Clinical Presentation</div>
<div class="toc-item"><div class="toc-num" style="background:rgba(239,68,68,0.3);color:#fca5a5;">5</div> Diagnosis — Lab & Imaging</div>
<div class="toc-item"><div class="toc-num" style="background:rgba(249,115,22,0.3);color:#fdba74;">6</div> Severity Classification</div>
</div>
<div>
<div class="toc-item"><div class="toc-num" style="background:rgba(234,179,8,0.3);color:#fde047;">7</div> Scoring Systems</div>
<div class="toc-item"><div class="toc-num" style="background:rgba(34,197,94,0.3);color:#86efac;">8</div> Initial Management</div>
<div class="toc-item"><div class="toc-num" style="background:rgba(6,182,212,0.3);color:#67e8f9;">9</div> Nutrition & Antibiotics</div>
<div class="toc-item"><div class="toc-num" style="background:rgba(59,130,246,0.3);color:#93c5fd;">10</div> Local Complications</div>
<div class="toc-item"><div class="toc-num" style="background:rgba(99,102,241,0.3);color:#a5b4fc;">11</div> Surgical & Interventional Rx</div>
<div class="toc-item"><div class="toc-num" style="background:rgba(168,85,247,0.3);color:#d8b4fe;">12</div> Special Scenarios & Follow-up</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 3 — SECTION: DEFINITION & EPIDEMIOLOGY
══════════════════════════════════════════════════ -->
<div class="slide slide-section">
<div class="section-icon">🔬</div>
<div class="section-number">01</div>
<div class="section-title">Definition & Epidemiology</div>
<div class="section-subtitle">Understanding the scope of acute pancreatitis</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 4 — DEFINITION & EPIDEMIOLOGY
══════════════════════════════════════════════════ -->
<div class="slide slide-content">
<div class="slide-heading blue">🔬 Definition & Epidemiology</div>
<div class="two-col flex-1">
<div>
<div class="card blue mb-3">
<div class="card-title blue">Definition (Revised Atlanta 2012)</div>
<div class="text-sm">A discrete episode of <em class="highlight">cellular injury and inflammation</em> in the pancreas, typically presenting with:</div>
<ul class="styled" style="margin-top:8px;">
<li>Abdominal pain (epigastric, radiating to back)</li>
<li>Nausea and vomiting</li>
<li>Elevated serum amylase or lipase (>3× ULN)</li>
<li>Radiographic evidence of pancreatic inflammation</li>
</ul>
<div class="text-xs" style="margin-top:8px; color:rgba(255,255,255,0.5);">Diagnosis requires ≥2 of 3 criteria</div>
</div>
<div class="alert info">
<span class="alert-icon">ℹ️</span>
<span>Acute and chronic pancreatitis exist on a <strong>continuum</strong> — recurrent AP can evolve into chronic pancreatitis with irreversible fibrosis.</span>
</div>
</div>
<div>
<div class="card cyan mb-3">
<div class="card-title cyan">Epidemiology</div>
<ul class="styled cyan">
<li>Incidence: <strong>33–74 per 100,000</strong> globally</li>
<li>~40 cases/100,000 in the United States</li>
<li>~300,000 US hospital admissions annually</li>
<li>Annual cost: $4–6 billion USD</li>
<li>Incidence <strong>rising</strong> — linked to obesity epidemic</li>
</ul>
</div>
<div class="card green">
<div class="card-title green">Outcomes</div>
<ul class="styled green">
<li>~80% mild, self-limiting (resolves in 3–5 days)</li>
<li>~20% develop complications</li>
<li>Overall mortality ~5%</li>
<li>Severe AP with infected necrosis: mortality 36–50%</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 5 — SECTION: ETIOLOGY
══════════════════════════════════════════════════ -->
<div class="slide slide-section" style="background: linear-gradient(135deg,#1e3a2f 0%,#14532d 100%);">
<div class="section-icon">⚗️</div>
<div class="section-number">02</div>
<div class="section-title">Etiology & Risk Factors</div>
<div class="section-subtitle">Gallstones + alcohol = ~80% of cases</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 6 — ETIOLOGY
══════════════════════════════════════════════════ -->
<div class="slide slide-content2">
<div class="slide-heading green">⚗️ Etiology of Acute Pancreatitis</div>
<div class="three-col flex-1">
<div>
<div class="card green mb-3">
<div class="card-title green">Mechanical (~50%)</div>
<ul class="styled green">
<li><strong>Gallstones</strong> — most common in US (40–50%)</li>
<li>Microlithiasis / biliary sludge</li>
<li>Pancreas divisum</li>
<li>Ampullary / periampullary tumors</li>
<li>Trauma (especially blunt)</li>
<li>Post-ERCP pancreatitis</li>
<li>Ascaris / parasitic obstruction</li>
</ul>
</div>
<div class="card blue">
<div class="card-title blue">Genetic</div>
<ul class="styled">
<li>PRSS1 (cationic trypsinogen) mutations</li>
<li>SPINK1 (trypsin inhibitor)</li>
<li>CFTR mutations</li>
<li>CTRC mutations</li>
</ul>
</div>
</div>
<div>
<div class="card orange mb-3">
<div class="card-title orange">Metabolic (~30%)</div>
<ul class="styled orange">
<li><strong>Alcohol</strong> — 2nd most common (~30%)</li>
<li>Hypertriglyceridemia (>1000 mg/dL = 5–10%)</li>
<li>Hypercalcemia (hyperparathyroidism)</li>
<li>Obesity (independent risk factor)</li>
</ul>
</div>
<div class="card yellow">
<div class="card-title yellow">Drugs (~5%)</div>
<ul class="styled yellow">
<li>Azathioprine / 6-MP</li>
<li>Thiazide diuretics</li>
<li>Estrogens / valproate</li>
<li>L-asparaginase</li>
<li>Anticonvulsants</li>
<li>GLP-1 agonists (emerging data)</li>
</ul>
</div>
</div>
<div>
<div class="card red mb-3">
<div class="card-title red">Infectious</div>
<ul class="styled red">
<li>Mumps virus</li>
<li>Coxsackievirus / Enteroviruses</li>
<li>EBV, CMV</li>
<li>Mycoplasma pneumoniae</li>
<li>Ascariasis (endemic regions)</li>
</ul>
</div>
<div class="card purple">
<div class="card-title purple">Vascular / Other</div>
<ul class="styled purple">
<li>Ischemia / shock</li>
<li>Atheroembolism</li>
<li>Polyarteritis nodosa</li>
<li>Autoimmune pancreatitis (IgG4)</li>
<li>Idiopathic (10–20%)</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 7 — SECTION: PATHOGENESIS
══════════════════════════════════════════════════ -->
<div class="slide slide-section" style="background: linear-gradient(135deg,#1e1b4b 0%,#4c1d95 100%);">
<div class="section-icon">🧬</div>
<div class="section-number">03</div>
<div class="section-title">Pathogenesis</div>
<div class="section-subtitle">Premature activation of digestive enzymes — the final common pathway</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 8 — PATHOGENESIS (with image)
══════════════════════════════════════════════════ -->
<div class="slide slide-content4">
<div class="slide-heading purple">🧬 Pathogenesis of Acute Pancreatitis</div>
<div style="display:grid; grid-template-columns:1fr 1.2fr; gap:20px; flex:1; height:calc(100% - 80px);">
<div style="display:flex; flex-direction:column; gap:12px;">
<div class="card purple">
<div class="card-title purple">Three Initiating Pathways</div>
<div class="step">
<div class="step-num" style="background:rgba(168,85,247,0.3);color:#d8b4fe;">1</div>
<div class="step-body">
<div class="step-title" style="color:#d8b4fe;">Pancreatic Duct Obstruction</div>
<div class="step-desc">Gallstone impaction → increased intraductal pressure → enzyme-rich interstitial fluid → fat necrosis → inflammatory cytokines → edema → vascular insufficiency</div>
</div>
</div>
<div class="step">
<div class="step-num" style="background:rgba(236,72,153,0.3);color:#f9a8d4;">2</div>
<div class="step-body">
<div class="step-title" style="color:#f9a8d4;">Primary Acinar Cell Injury</div>
<div class="step-desc">Alcohol, hypertriglyceridemia, ischemia, viruses, drugs → direct toxicity → release of intracellular proenzymes & lysosomal hydrolases</div>
</div>
</div>
<div class="step">
<div class="step-num" style="background:rgba(99,102,241,0.3);color:#a5b4fc;">3</div>
<div class="step-body">
<div class="step-title" style="color:#a5b4fc;">Defective Intracellular Transport</div>
<div class="step-desc">Proenzymes & lysosomal hydrolases co-packaged → intracellular trypsinogen activation → lysosomal rupture</div>
</div>
</div>
</div>
<div class="card blue">
<div class="card-title blue">Downstream Effects of Trypsin Activation</div>
<div class="criteria">
<div class="crit-item"><strong style="color:#f9a8d4;">Proteases</strong><div class="crit-val">Parenchymal autodigestion</div></div>
<div class="crit-item"><strong style="color:#fdba74;">Lipase/Phospholipase</strong><div class="crit-val">Fat necrosis</div></div>
<div class="crit-item"><strong style="color:#fca5a5;">Elastase</strong><div class="crit-val">Vessel wall damage, hemorrhage</div></div>
<div class="crit-item"><strong style="color:#86efac;">Kallikrein/Kinin</strong><div class="crit-val">Vasodilation, edema</div></div>
<div class="crit-item"><strong style="color:#67e8f9;">Complement/Clotting</strong><div class="crit-val">Systemic inflammation</div></div>
<div class="crit-item"><strong style="color:#d8b4fe;">Cytokines (TNF-α, IL-1, IL-6)</strong><div class="crit-val">SIRS → organ failure</div></div>
</div>
</div>
</div>
<div class="img-panel">
<img src="https://cdn.orris.care/cdss_images/fd98dac14c61b2d86411622cbd53461c2f5b89022bb72abcc2043a8368623417.png" alt="Pathogenesis of acute pancreatitis diagram from Robbins & Kumar Basic Pathology" style="object-fit:contain; background:#111;" />
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 9 — SECTION: CLINICAL PRESENTATION
══════════════════════════════════════════════════ -->
<div class="slide slide-section" style="background: linear-gradient(135deg,#450a0a 0%,#7f1d1d 100%);">
<div class="section-icon">🩺</div>
<div class="section-number">04</div>
<div class="section-title">Clinical Presentation</div>
<div class="section-subtitle">Signs, symptoms and physical findings</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 10 — CLINICAL FEATURES
══════════════════════════════════════════════════ -->
<div class="slide slide-content3">
<div class="slide-heading red">🩺 Clinical Presentation</div>
<div class="two-col flex-1">
<div>
<div class="card red mb-3">
<div class="card-title red">Symptoms</div>
<ul class="styled red">
<li><strong>Epigastric pain</strong> — abrupt onset, severe, constant</li>
<li>Radiates to back in ~50% (band-like)</li>
<li>Worse lying supine; relieved leaning forward</li>
<li>Nausea and vomiting (often persistent)</li>
<li>Anorexia, bloating, abdominal distension</li>
</ul>
</div>
<div class="card orange">
<div class="card-title orange">Physical Examination</div>
<ul class="styled orange">
<li>Epigastric tenderness ± guarding</li>
<li>Low-grade fever (38–39°C)</li>
<li>Tachycardia, hypotension (hypovolemia)</li>
<li>Reduced bowel sounds (ileus)</li>
<li><strong>Grey Turner's sign</strong> — flank ecchymosis (hemorrhagic AP)</li>
<li><strong>Cullen's sign</strong> — periumbilical ecchymosis (hemorrhagic AP)</li>
<li>Scleral icterus (biliary obstruction)</li>
</ul>
</div>
</div>
<div>
<div class="card yellow mb-3">
<div class="card-title yellow">Differential Diagnosis</div>
<ul class="styled yellow">
<li>Perforated peptic ulcer</li>
<li>Acute cholecystitis / biliary colic</li>
<li>Mesenteric ischemia</li>
<li>Aortic dissection / aneurysm</li>
<li>Inferior MI (posterior wall)</li>
<li>Small bowel obstruction</li>
<li>Gastric volvulus</li>
</ul>
</div>
<div class="alert warning">
<span class="alert-icon">⚠️</span>
<span><strong>Grey Turner and Cullen signs</strong> appear late (2–3 days) and indicate severe hemorrhagic necrosis. Their absence does NOT exclude severe disease.</span>
</div>
<div class="alert danger">
<span class="alert-icon">🚨</span>
<span><strong>Red flags for severe disease:</strong> Tachycardia >100, RR >20, SpO₂ <95%, Cr >1.8 mg/dL, altered mental status, age >55, BMI >30, hematocrit >44%</span>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 11 — SECTION: DIAGNOSIS
══════════════════════════════════════════════════ -->
<div class="slide slide-section" style="background: linear-gradient(135deg,#0c2340 0%,#1e40af 100%);">
<div class="section-icon">🔍</div>
<div class="section-number">05</div>
<div class="section-title">Diagnosis</div>
<div class="section-subtitle">Laboratory workup & imaging evaluation</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 12 — LABORATORY DIAGNOSIS
══════════════════════════════════════════════════ -->
<div class="slide slide-content">
<div class="slide-heading blue">🔬 Laboratory Evaluation</div>
<div class="two-col flex-1">
<div>
<div class="card blue mb-3">
<div class="card-title blue">Diagnostic Enzymes</div>
<div class="text-sm mb-2"><strong style="color:#67e8f9;">Serum Lipase (preferred)</strong></div>
<ul class="styled">
<li>Rises within 4–8 hours of onset</li>
<li>Peaks at 24 hours; elevated for <strong>8–14 days</strong></li>
<li>More specific than amylase (>3× ULN diagnostic)</li>
<li>Not elevated in salivary disease, bowel perforation</li>
</ul>
<div class="text-sm mb-2 mt-2"><strong style="color:#93c5fd;">Serum Amylase</strong></div>
<ul class="styled">
<li>Rises within 2–12 hours; normalizes in 3–5 days</li>
<li>Less specific (also elevated in salivary disorders, macroamylasemia)</li>
<li>>3× ULN used as diagnostic threshold</li>
</ul>
</div>
<div class="alert info">
<span class="alert-icon">📌</span>
<span>Enzyme levels do <strong>NOT</strong> correlate with disease severity. Normal lipase does not rule out AP (e.g., hypertriglyceridemia-induced AP can show falsely low values).</span>
</div>
</div>
<div>
<div class="card cyan mb-3">
<div class="card-title cyan">Additional Laboratory Tests</div>
<ul class="styled cyan">
<li><strong>CBC</strong> — hematocrit >44% predicts severity; leukocytosis</li>
<li><strong>CRP</strong> — >150 mg/L at 48h predicts necrosis</li>
<li><strong>BUN</strong> — elevated / rising BUN correlates with severity</li>
<li><strong>Creatinine</strong> — AKI assessment</li>
<li><strong>LFTs / bilirubin</strong> — ALT >3× ULN suggests biliary etiology</li>
<li><strong>Calcium</strong> — hypercalcemia (etiology) or hypocalcemia (severity)</li>
<li><strong>Triglycerides</strong> — rule out HTG-induced AP (>1000 mg/dL)</li>
<li><strong>Glucose</strong> — hyperglycemia indicates acinar destruction</li>
<li><strong>ABG/SpO₂</strong> — respiratory compromise, ARDS</li>
<li><strong>Blood cultures</strong> — if sepsis suspected</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 13 — IMAGING
══════════════════════════════════════════════════ -->
<div class="slide slide-content">
<div class="slide-heading cyan">🖼️ Imaging in Acute Pancreatitis</div>
<div style="display:grid; grid-template-columns:1.1fr 1fr; gap:20px; flex:1; height:calc(100% - 80px);">
<div style="display:flex; flex-direction:column; gap:12px; overflow-y:auto;">
<div class="card cyan">
<div class="card-title cyan">Contrast-Enhanced CT (CECT) — Gold Standard</div>
<ul class="styled cyan">
<li><strong>Indication:</strong> Diagnostic uncertainty, suspected complications, no improvement at 48–72h</li>
<li>NOT required for mild, straightforward AP</li>
<li>Best performed ≥72h after onset (allows necrosis to declare)</li>
<li>Detects: necrosis, fluid collections, vascular complications</li>
<li>Non-enhancing pancreatic parenchyma = necrosis</li>
<li>Gas in necrosis = infected necrosis</li>
</ul>
</div>
<div class="card blue">
<div class="card-title blue">Abdominal Ultrasound — First-line</div>
<ul class="styled">
<li>Indicated in <strong>all</strong> first presentations</li>
<li>Identifies gallstones, biliary dilation, sludge</li>
<li>Limited visualization of pancreas (bowel gas)</li>
<li>Should be performed within 24h of admission</li>
</ul>
</div>
<div class="card purple">
<div class="card-title purple">MRI / MRCP</div>
<ul class="styled purple">
<li>Alternative to CT (no radiation, better soft-tissue)</li>
<li>Superior for detecting ductal disruption</li>
<li>MRCP preferred over diagnostic ERCP</li>
<li>Useful in pregnancy, renal impairment (no contrast needed)</li>
</ul>
</div>
</div>
<div style="display:flex; flex-direction:column; gap:12px;">
<div class="img-panel" style="flex:1;">
<img src="https://cdn.orris.care/cdss_images/b9e46eb96fe2e5ad3a95619b631dddfb285b3cce9268c86f228eff38925c5bd5.png" alt="CECT showing necrotizing pancreatitis" style="object-fit:cover; width:100%; height:100%; background:#000;" />
</div>
<div class="text-xs" style="text-align:center; color:rgba(255,255,255,0.4);">CECT: Hypoenhancing necrosis (asterisk) of pancreatic body/tail with surrounding edema. Small amount of enhancing parenchyma at head (arrow). — Current Surgical Therapy 14e</div>
<div class="alert warning">
<span class="alert-icon">⚠️</span>
<span>CT contrast may worsen renal function in severe AP with AKI. Weigh risks; use MRI when creatinine is significantly elevated.</span>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 14 — SECTION: SEVERITY
══════════════════════════════════════════════════ -->
<div class="slide slide-section" style="background: linear-gradient(135deg,#1c1400 0%,#713f12 100%);">
<div class="section-icon">📊</div>
<div class="section-number">06</div>
<div class="section-title">Severity Classification</div>
<div class="section-subtitle">Revised Atlanta Classification 2012</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 15 — SEVERITY CLASSIFICATION
══════════════════════════════════════════════════ -->
<div class="slide slide-content">
<div class="slide-heading yellow">📊 Revised Atlanta Classification (2012)</div>
<div style="flex:1; display:flex; flex-direction:column; gap:16px;">
<table class="sev-table">
<thead>
<tr>
<th>Grade</th>
<th>Organ Failure</th>
<th>Local/Systemic Complications</th>
<th>Mortality</th>
<th>Typical Hospital Stay</th>
</tr>
</thead>
<tbody>
<tr>
<td><span class="pill green">Mild</span></td>
<td>Absent</td>
<td>Absent</td>
<td style="color:#86efac;"><5% (very rare)</td>
<td>3–5 days</td>
</tr>
<tr>
<td><span class="pill yellow">Moderately Severe</span></td>
<td>Transient (<48 hours)</td>
<td>Present (without persistent organ failure)</td>
<td style="color:#fde047;">Low to moderate</td>
<td>1–2 weeks</td>
</tr>
<tr>
<td><span class="pill red">Severe</span></td>
<td>Persistent (>48 hours)</td>
<td>Present (± infected necrosis)</td>
<td style="color:#fca5a5;">36–50%; extremely high with infected necrosis</td>
<td>Weeks to months (ICU)</td>
</tr>
</tbody>
</table>
<div class="alert info">
<span class="alert-icon">📌</span>
<span>Severity grade may <strong>evolve throughout the clinical course</strong>. Reassess at 24h, 48h, 7 days, then weekly. Early severity prediction guides triage (ward vs HDU/ICU).</span>
</div>
<div class="two-col">
<div class="card blue">
<div class="card-title blue">Organ Failure Assessment (Modified Marshall Score)</div>
<ul class="styled">
<li><strong>Respiratory:</strong> PaO₂/FiO₂ <300</li>
<li><strong>Renal:</strong> Creatinine >1.9 mg/dL</li>
<li><strong>Cardiovascular:</strong> Systolic BP <90 despite fluid resuscitation</li>
<li>Score ≥2 in any organ system = organ failure</li>
</ul>
</div>
<div class="card red">
<div class="card-title red">Predictors of Severe AP (at Admission)</div>
<ul class="styled red">
<li>Age >55, BMI >30, comorbidities</li>
<li>Hematocrit >44%, BUN >20 mg/dL (rising)</li>
<li>CRP >150 mg/L at 48h</li>
<li>SIRS criteria present (>2 criteria)</li>
<li>Pleural effusion on chest X-ray</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 16 — SCORING SYSTEMS
══════════════════════════════════════════════════ -->
<div class="slide slide-content">
<div class="slide-heading orange">🧮 Severity Scoring Systems</div>
<div class="two-col flex-1">
<div>
<div class="card orange mb-3">
<div class="card-title orange">BISAP Score (Bedside Index of Severity in AP)</div>
<div class="text-xs mb-2">One point each (assess within 24h of admission):</div>
<ul class="styled orange">
<li><strong>B</strong>UN >25 mg/dL</li>
<li><strong>I</strong>mpaired mental status (GCS <15)</li>
<li><strong>S</strong>IRS criteria (≥2 present)</li>
<li><strong>A</strong>ge >60 years</li>
<li><strong>P</strong>leural effusion on imaging</li>
</ul>
<div class="text-xs" style="margin-top:8px; color:#fdba74;">Score ≥3 → high risk of organ failure and mortality (>15%)</div>
</div>
<div class="card yellow">
<div class="card-title yellow">Ranson's Criteria</div>
<div class="text-xs mb-2" style="color:#fde047;">At admission (5 criteria) + at 48h (6 criteria)</div>
<div style="display:grid; grid-template-columns:1fr 1fr; gap:8px;">
<div>
<div class="text-xs" style="color:#fde047; font-weight:700; margin-bottom:4px;">On Admission</div>
<ul class="styled yellow" style="font-size:12px;">
<li>Age >55</li>
<li>WBC >16,000/μL</li>
<li>Glucose >200 mg/dL</li>
<li>AST >250 U/L</li>
<li>LDH >350 U/L</li>
</ul>
</div>
<div>
<div class="text-xs" style="color:#fde047; font-weight:700; margin-bottom:4px;">At 48 Hours</div>
<ul class="styled yellow" style="font-size:12px;">
<li>HCT drop >10%</li>
<li>BUN rise >5 mg/dL</li>
<li>Ca <8 mg/dL</li>
<li>PaO₂ <60 mmHg</li>
<li>Base deficit >4</li>
<li>Fluid sequestration >6L</li>
</ul>
</div>
</div>
<div class="text-xs" style="margin-top:8px; color:#fde047;">≥3 criteria → severe disease</div>
</div>
</div>
<div>
<div class="card cyan mb-3">
<div class="card-title cyan">CT Severity Index (CTSI / Balthazar)</div>
<div class="text-xs mb-2">Grade A–E (0–4 points) + Necrosis score (0–6 points) = Total CTSI (max 10)</div>
<table class="sev-table" style="font-size:12px;">
<thead><tr><th>Balthazar Grade</th><th>Points</th><th>Necrosis</th><th>Points</th></tr></thead>
<tbody>
<tr><td>A: Normal</td><td>0</td><td>None</td><td>0</td></tr>
<tr><td>B: Focal/diffuse enlargement</td><td>1</td><td><30%</td><td>2</td></tr>
<tr><td>C: Peripancreatic inflammation</td><td>2</td><td>30–50%</td><td>4</td></tr>
<tr><td>D: Single fluid collection</td><td>3</td><td>>50%</td><td>6</td></tr>
<tr><td>E: ≥2 fluid collections / gas</td><td>4</td><td></td><td></td></tr>
</tbody>
</table>
<div class="text-xs" style="margin-top:8px; color:#67e8f9;">CTSI 7–10 → morbidity ~92%, mortality ~17%</div>
</div>
<div class="card purple">
<div class="card-title purple">APACHE II Score</div>
<ul class="styled purple">
<li>12-variable physiologic score</li>
<li>Can be calculated on admission and daily</li>
<li>Score ≥8 → predicted mortality >15%</li>
<li>Advantage: dynamic reassessment; validated for ICU</li>
<li>Disadvantage: complex, requires all 12 variables</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 17 — SECTION: INITIAL MANAGEMENT
══════════════════════════════════════════════════ -->
<div class="slide slide-section" style="background: linear-gradient(135deg,#064e3b 0%,#065f46 100%);">
<div class="section-icon">💉</div>
<div class="section-number">07</div>
<div class="section-title">Initial Management</div>
<div class="section-subtitle">Fluid resuscitation · analgesia · monitoring · etiology-directed therapy</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 18 — INITIAL MANAGEMENT
══════════════════════════════════════════════════ -->
<div class="slide slide-content2">
<div class="slide-heading green">💉 Initial Management — First 24–48 Hours</div>
<div class="two-col flex-1">
<div>
<div class="card green mb-3">
<div class="card-title green">Fluid Resuscitation (CRITICAL)</div>
<ul class="styled green">
<li><strong>Goal-directed:</strong> Start within 1–2h; target UO ≥0.5 mL/kg/h</li>
<li><strong>Lactated Ringer's</strong> preferred over normal saline (ACG 2024, IAP 2025)</li>
<li>Initial rate: <strong>250–500 mL/hour</strong> for 12–24h</li>
<li>Moderate severity: 2.5–4 L over 24h</li>
<li>Reassess every 2–4h (HR, BP, BUN, HCT, UO)</li>
<li><strong>Avoid over-resuscitation</strong> → abdominal compartment syndrome</li>
<li>Reduce rate once hemodynamically stable</li>
</ul>
</div>
<div class="card blue">
<div class="card-title blue">Analgesia & Comfort</div>
<ul class="styled">
<li><strong>IV opioids</strong> (morphine, hydromorphone) — effective, safe</li>
<li>NSAIDS / ketorolac (mild-moderate, no AKI)</li>
<li>Epidural analgesia for severe, refractory pain</li>
<li>Nasogastric tube only if intractable vomiting / ileus</li>
<li>Antiemetics (ondansetron, metoclopramide)</li>
</ul>
</div>
</div>
<div>
<div class="card cyan mb-3">
<div class="card-title cyan">Monitoring & Triage</div>
<ul class="styled cyan">
<li><strong>Mild AP:</strong> General ward; re-assess severity at 24h and 48h</li>
<li><strong>Moderately severe / Severe:</strong> HDU or ICU admission</li>
<li>Vital signs hourly in first 24h if unstable</li>
<li>Monitor: HR, BP, UO, RR, SpO₂, temperature</li>
<li>Daily labs: CBC, BMP, LFTs, lipase, CRP</li>
<li>Chest X-ray: pleural effusion, ARDS</li>
<li>DVT prophylaxis (LMWH when bleeding risk acceptable)</li>
</ul>
</div>
<div class="card yellow">
<div class="card-title yellow">Etiology-Specific Early Interventions</div>
<ul class="styled yellow">
<li><strong>Biliary pancreatitis + cholangitis:</strong> Urgent ERCP within 24h</li>
<li><strong>Biliary pancreatitis (no cholangitis):</strong> ERCP not routinely indicated; laparoscopic cholecystectomy before discharge</li>
<li><strong>HTG pancreatitis (TG >1000):</strong> Insulin infusion, consider plasmapheresis in severe/refractory cases</li>
<li><strong>Alcohol-induced AP:</strong> Brief intervention; thiamine supplementation</li>
<li><strong>Drug-induced:</strong> Discontinue offending agent</li>
<li><strong>Hypercalcemia:</strong> Treat underlying cause (hyperparathyroidism)</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 19 — NUTRITION & ANTIBIOTICS
══════════════════════════════════════════════════ -->
<div class="slide slide-content2">
<div class="slide-heading cyan">🍽️ Nutrition & Antibiotic Therapy</div>
<div class="two-col flex-1">
<div>
<div class="card green mb-3">
<div class="card-title green">Nutritional Support</div>
<div class="alert success" style="margin-bottom:12px; padding:10px 12px;">
<span class="alert-icon">✅</span>
<span><strong>Enteral nutrition is preferred</strong> over parenteral nutrition and should be initiated <strong>within 24–48h</strong> in moderate-to-severe AP (IAP 2025, ACG 2024).</span>
</div>
<ul class="styled green">
<li><strong>Mild AP:</strong> Start oral diet as tolerated (no need to wait for lipase normalization)</li>
<li><strong>Low-fat solid diet</strong> safe as first oral feeding (vs. liquid diet)</li>
<li><strong>Nasojejunal feeding</strong> preferred in severe AP; nasogastric feeding may be equivalent</li>
<li>Early enteral nutrition:
<ul class="styled" style="margin-top:4px; margin-left:12px;">
<li>Maintains gut mucosal integrity</li>
<li>Reduces bacterial translocation</li>
<li>Decreases infectious complications</li>
<li>Reduces ICU length of stay</li>
</ul>
</li>
<li><strong>TPN:</strong> Only if enteral route not feasible (prolonged ileus, fistula)</li>
</ul>
</div>
</div>
<div>
<div class="card red mb-3">
<div class="card-title red">Antibiotic Therapy</div>
<div class="alert danger" style="margin-bottom:12px; padding:10px 12px;">
<span class="alert-icon">🚫</span>
<span><strong>Prophylactic antibiotics are NOT recommended</strong> for sterile necrosis (strong evidence against — IAP 2025, ACG 2024).</span>
</div>
<ul class="styled red">
<li><strong>Indications for antibiotics:</strong>
<ul class="styled" style="margin-top:4px; margin-left:12px;">
<li>Documented infected pancreatic necrosis</li>
<li>Concomitant cholangitis or sepsis</li>
<li>Extrapancreatic infection</li>
</ul>
</li>
<li><strong>Empiric regimen:</strong> Carbapenems (imipenem or meropenem) for good pancreatic tissue penetration</li>
<li>Alternative: Fluoroquinolone + metronidazole</li>
<li>Cover gram-negative and gram-positive organisms</li>
<li><strong>Duration:</strong> Until source control achieved; guided by cultures</li>
</ul>
</div>
<div class="card purple">
<div class="card-title purple">Other Supportive Measures</div>
<ul class="styled purple">
<li>Insulin infusion for hyperglycemia</li>
<li>Continuous pulse oximetry; supplemental O₂ / mechanical ventilation if ARDS</li>
<li>Renal replacement therapy for severe AKI</li>
<li>Proton pump inhibitors (stress ulcer prophylaxis)</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 20 — SECTION: COMPLICATIONS
══════════════════════════════════════════════════ -->
<div class="slide slide-section" style="background: linear-gradient(135deg,#3b0a0a 0%,#7c1a1a 100%);">
<div class="section-icon">⚡</div>
<div class="section-number">08</div>
<div class="section-title">Complications</div>
<div class="section-subtitle">Local & systemic — recognition and management</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 21 — LOCAL COMPLICATIONS
══════════════════════════════════════════════════ -->
<div class="slide slide-content3">
<div class="slide-heading red">⚡ Local Complications (Revised Atlanta 2012)</div>
<div class="two-col flex-1">
<div>
<div class="card green mb-3">
<div class="card-title green">Interstitial Edematous Pancreatitis</div>
<ul class="styled green">
<li>Acute inflammation without necrosis</li>
<li><strong>Acute Peripancreatic Fluid Collection (APFC)</strong>
<ul class="styled" style="margin-left:12px; margin-top:4px;">
<li>Homogenous, non-encapsulated</li>
<li>Within 4 weeks; most resolve spontaneously</li>
</ul>
</li>
<li><strong>Pancreatic Pseudocyst</strong>
<ul class="styled" style="margin-left:12px; margin-top:4px;">
<li>Encapsulated, well-defined wall; >4 weeks</li>
<li>No significant necrosis</li>
<li>Most resolve; intervene if symptomatic</li>
</ul>
</li>
</ul>
</div>
<div class="card orange">
<div class="card-title orange">Other Local Complications</div>
<ul class="styled orange">
<li>Hemorrhagic pancreatitis</li>
<li>Gastric outlet obstruction</li>
<li>Splenic / portal vein thrombosis</li>
<li>Pseudoaneurysm (splenic artery)</li>
<li>Colonic infarction</li>
<li>Pancreatic fistula / ductal disruption</li>
</ul>
</div>
</div>
<div>
<div class="card red mb-3">
<div class="card-title red">Necrotizing Pancreatitis</div>
<ul class="styled red">
<li>Necrosis of pancreatic parenchyma and/or peripancreatic tissue</li>
<li><strong>Acute Necrotic Collection (ANC)</strong>
<ul class="styled" style="margin-left:12px; margin-top:4px;">
<li>Fluid + necrosis; within 4 weeks</li>
<li>Initially sterile — may become infected</li>
</ul>
</li>
<li><strong>Walled-Off Necrosis (WON)</strong>
<ul class="styled" style="margin-left:12px; margin-top:4px;">
<li>Mature, encapsulated necrotic collection</li>
<li>Well-defined inflammatory wall; >4 weeks</li>
<li>May be sterile or infected</li>
</ul>
</li>
</ul>
</div>
<div class="card yellow">
<div class="card-title yellow">Systemic Complications</div>
<ul class="styled yellow">
<li>Acute kidney injury (AKI)</li>
<li>Acute respiratory distress syndrome (ARDS)</li>
<li>Sepsis / septic shock</li>
<li>Abdominal compartment syndrome</li>
<li>Adynamic ileus</li>
<li>DIC</li>
<li>Hyperglycemia / diabetes</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 22 — INFECTED NECROSIS & STEP-UP
══════════════════════════════════════════════════ -->
<div class="slide slide-content3">
<div class="slide-heading red">🔪 Infected Pancreatic Necrosis — Step-Up Approach</div>
<div class="two-col flex-1">
<div>
<div class="alert danger" style="margin-bottom:14px;">
<span class="alert-icon">🚨</span>
<span><strong>Suspect infected necrosis</strong> when: fever/leukocytosis persists >7–10 days, gas in necrotic collection on CT, or FNA culture positive for bacteria/fungi</span>
</div>
<div class="card red mb-3">
<div class="card-title red">Diagnostic Approach</div>
<ul class="styled red">
<li>CECT: gas in necrosis = pathognomonic for infection</li>
<li>CT-guided FNA (if no gas but suspicion high)</li>
<li>Gram stain + culture to guide antibiotics</li>
<li><strong>Do NOT intervene on sterile necrosis</strong> unless symptomatic mass effect</li>
</ul>
</div>
<div class="card orange">
<div class="card-title orange">PANTER Trial Evidence</div>
<ul class="styled orange">
<li>Step-up vs open necrosectomy: composite endpoint reduced significantly (12% vs 50%)</li>
<li>Major complications & new organ failure reduced</li>
<li>Mortality similar short-term; long-term follow-up confirmed step-up superiority</li>
<li>Step-up = standard of care for infected necrosis</li>
</ul>
</div>
</div>
<div>
<div class="card blue">
<div class="card-title blue">Step-Up Approach Algorithm</div>
<div class="flow">
<div class="flow-step" style="border-color:rgba(59,130,246,0.4);">
<strong style="color:#93c5fd;">Step 1: Broad-Spectrum Antibiotics</strong>
Carbapenems (imipenem/meropenem); cover gram-negative + gram-positive organisms
</div>
<div class="flow-arrow">↓ (if no improvement after 72h)</div>
<div class="flow-step" style="border-color:rgba(168,85,247,0.4);">
<strong style="color:#d8b4fe;">Step 2: Percutaneous / Endoscopic Drainage</strong>
CT-guided percutaneous catheter drainage OR endoscopic transmural drainage (transgastric/transduodenal) — first intervention of choice
</div>
<div class="flow-arrow">↓ (if inadequate response)</div>
<div class="flow-step" style="border-color:rgba(249,115,22,0.4);">
<strong style="color:#fdba74;">Step 3: Minimally Invasive Necrosectomy</strong>
VARD (video-assisted retroperitoneal debridement) or MIRP (minimally invasive retroperitoneal pancreatic necrosectomy) or Direct Endoscopic Necrosectomy (DEN)
</div>
<div class="flow-arrow">↓ (last resort)</div>
<div class="flow-step" style="border-color:rgba(239,68,68,0.4);">
<strong style="color:#fca5a5;">Step 4: Open Necrosectomy</strong>
Reserved for failed minimally invasive approaches; associated with high morbidity
</div>
</div>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 23 — BILIARY PANCREATITIS & ERCP
══════════════════════════════════════════════════ -->
<div class="slide slide-content">
<div class="slide-heading cyan">🔭 Biliary Pancreatitis — ERCP & Cholecystectomy</div>
<div class="two-col flex-1">
<div>
<div class="card cyan mb-3">
<div class="card-title cyan">When to Perform ERCP in Biliary Pancreatitis?</div>
<div class="alert danger" style="margin-bottom:10px; padding:9px 12px;">
<span class="alert-icon">🚨</span>
<span><strong>Cholangitis + biliary pancreatitis:</strong> Urgent ERCP within 24 hours</span>
</div>
<div class="alert warning" style="margin-bottom:10px; padding:9px 12px;">
<span class="alert-icon">⚠️</span>
<span><strong>Persistent biliary obstruction / CBD stone without cholangitis:</strong> ERCP within 72h</span>
</div>
<div class="alert success" style="margin-bottom:10px; padding:9px 12px;">
<span class="alert-icon">✅</span>
<span><strong>Mild biliary AP without CBD stone or cholangitis:</strong> ERCP is NOT indicated; proceed to cholecystectomy</span>
</div>
<ul class="styled cyan">
<li>MRCP preferred over diagnostic ERCP to detect CBD stones</li>
<li>EUS is highly sensitive for microlithiasis / biliary sludge</li>
</ul>
</div>
</div>
<div>
<div class="card green mb-3">
<div class="card-title green">Cholecystectomy — When & How?</div>
<ul class="styled green">
<li>All patients with gallstone pancreatitis should undergo <strong>cholecystectomy</strong> to prevent recurrence</li>
<li><strong>Mild AP:</strong> Laparoscopic cholecystectomy during same admission (safe, preferred)</li>
<li><strong>Moderate/Severe AP:</strong> Delay until clinical improvement and collections resolve (usually 6–8 weeks)</li>
<li>Failure to perform cholecystectomy → recurrence rate up to 30–60%</li>
</ul>
</div>
<div class="card purple">
<div class="card-title purple">Post-ERCP Pancreatitis Prevention</div>
<ul class="styled purple">
<li><strong>Rectal indomethacin 100 mg</strong> — routine prophylaxis in average-risk patients (reduces risk by ~50%)</li>
<li>Pancreatic duct stenting — for high-risk ERCP</li>
<li>Hydration with LR peri-procedurally</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 24 — SPECIAL SCENARIOS
══════════════════════════════════════════════════ -->
<div class="slide slide-content4">
<div class="slide-heading purple">🌟 Special Clinical Scenarios</div>
<div class="three-col flex-1">
<div>
<div class="card purple mb-3">
<div class="card-title purple">Hypertriglyceridemia-Induced AP</div>
<ul class="styled purple">
<li>TG >1000 mg/dL causative</li>
<li>Lipase may be falsely low</li>
<li>Insulin infusion (lowers TG rapidly)</li>
<li>IV heparin (activates lipoprotein lipase)</li>
<li>Plasmapheresis in severe/refractory cases</li>
<li>Long-term: fibrates, omega-3, dietary fat restriction</li>
</ul>
</div>
<div class="card blue">
<div class="card-title blue">Pregnancy-Associated AP</div>
<ul class="styled">
<li>Gallstones most common cause</li>
<li>MRCP/EUS — avoid radiation</li>
<li>Early enteral nutrition important</li>
<li>ERCP safe in 2nd trimester (lead shielding)</li>
<li>Cholecystectomy — 2nd trimester preferred</li>
<li>Multidisciplinary team approach</li>
</ul>
</div>
</div>
<div>
<div class="card orange mb-3">
<div class="card-title orange">Autoimmune Pancreatitis (AIP)</div>
<ul class="styled orange">
<li><strong>Type 1:</strong> IgG4-related; older males; responds to steroids</li>
<li><strong>Type 2:</strong> IBD-associated; steroid responsive</li>
<li>Key: rule out malignancy (mimics pancreatic cancer)</li>
<li>Diagnostic criteria: ICDC / HISORt</li>
<li>IgG4 serology, CT "sausage pancreas" appearance</li>
<li>Steroid trial: Prednisone 40 mg/day × 4 weeks</li>
</ul>
</div>
<div class="card yellow">
<div class="card-title yellow">Recurrent Acute Pancreatitis</div>
<ul class="styled yellow">
<li>Defined as ≥2 discrete episodes</li>
<li>Evaluate for occult biliary disease (EUS/MRCP)</li>
<li>Genetic testing (PRSS1, SPINK1, CFTR, CTRC)</li>
<li>Screen for pancreatic malignancy</li>
<li>Address modifiable factors: alcohol, smoking, hypertriglyceridemia</li>
</ul>
</div>
</div>
<div>
<div class="card red mb-3">
<div class="card-title red">Abdominal Compartment Syndrome</div>
<ul class="styled red">
<li>Intraabdominal pressure >20 mmHg + organ dysfunction</li>
<li>Caused by aggressive fluid resuscitation + ileus</li>
<li>Monitor bladder pressure in at-risk patients</li>
<li>Treatment: decompressive measures, reduce fluid input</li>
<li>Surgical decompression may be required</li>
</ul>
</div>
<div class="card cyan">
<div class="card-title cyan">Pediatric Acute Pancreatitis</div>
<ul class="styled cyan">
<li>Common causes: trauma, medications, systemic disease, biliary (by age)</li>
<li>Valproate, L-asparaginase, prednisone — common drug causes</li>
<li>Genetic testing after recurrent episodes</li>
<li>HUS most common systemic cause in studies</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 25 — DISCHARGE & FOLLOW-UP
══════════════════════════════════════════════════ -->
<div class="slide slide-content2">
<div class="slide-heading green">🏠 Discharge Criteria & Follow-Up</div>
<div class="two-col flex-1">
<div>
<div class="card green mb-3">
<div class="card-title green">Criteria for Safe Discharge</div>
<ul class="styled green">
<li>Pain controlled on oral analgesia</li>
<li>Tolerating oral diet (solid foods preferred)</li>
<li>Afebrile; hemodynamically stable</li>
<li>No evidence of ongoing organ failure</li>
<li>No new complications on repeat imaging</li>
<li>Underlying etiology identified and addressed</li>
<li>Appropriate outpatient follow-up arranged</li>
</ul>
</div>
<div class="card blue">
<div class="card-title blue">Long-Term Follow-Up</div>
<ul class="styled">
<li>Cholecystectomy before discharge (biliary AP)</li>
<li>Lipid management + dietary counseling (HTG-AP)</li>
<li>Alcohol cessation (alcoholic AP)</li>
<li>Pancreatic exocrine insufficiency (PEI) screen — check for steatorrhea</li>
<li>Pancreatic endocrine function — screen for new-onset diabetes (3A)</li>
<li>Imaging follow-up for fluid collections at 6–8 weeks</li>
<li>Pancreatic cancer screening in idiopathic AP (especially age >40)</li>
</ul>
</div>
</div>
<div>
<div class="card orange mb-3">
<div class="card-title orange">Prevention of Recurrence</div>
<ul class="styled orange">
<li><strong>Gallstone AP:</strong> Same-admission cholecystectomy (reduces 30-day readmission)</li>
<li><strong>Alcohol-induced:</strong> Brief motivational intervention; referral to addiction services</li>
<li><strong>Smoking cessation:</strong> Independent risk factor for recurrence and progression to chronic pancreatitis</li>
<li><strong>HTG:</strong> Fibrates, dietary fat restriction, omega-3 fatty acids</li>
<li><strong>Drug-induced:</strong> Avoid re-challenge with causative drug</li>
<li><strong>Idiopathic:</strong> EUS/MRCP to identify occult biliary disease</li>
</ul>
</div>
<div class="card red">
<div class="card-title red">Complications to Screen for at Follow-Up</div>
<ul class="styled red">
<li>Walled-off necrosis (WON) development</li>
<li>Pseudocyst persistence or enlargement</li>
<li>New-onset diabetes mellitus (Type 3c)</li>
<li>Exocrine pancreatic insufficiency (EPI)</li>
<li>Progression to chronic pancreatitis</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 26 — MANAGEMENT ALGORITHM (SUMMARY)
══════════════════════════════════════════════════ -->
<div class="slide slide-content">
<div class="slide-heading blue">🗺️ Acute Pancreatitis — Management Algorithm</div>
<div style="display:grid; grid-template-columns:1fr 1fr 1fr; gap:12px; flex:1;">
<div>
<div style="text-align:center; padding:8px; background:rgba(59,130,246,0.15); border-radius:8px; font-size:13px; font-weight:700; color:#93c5fd; margin-bottom:10px; border:1px solid rgba(59,130,246,0.3);">ADMISSION</div>
<div class="flow">
<div class="flow-step" style="border-color:rgba(59,130,246,0.3); font-size:12px;">
<strong style="color:#93c5fd;">Confirm Diagnosis</strong>
≥2 of 3: Pain + lipase/amylase >3×ULN + CT findings
</div>
<div class="flow-arrow" style="font-size:14px;">↓</div>
<div class="flow-step" style="border-color:rgba(99,102,241,0.3); font-size:12px;">
<strong style="color:#a5b4fc;">Assess Etiology</strong>
US (gallstones), LFTs, lipase, TG, Ca, alcohol hx
</div>
<div class="flow-arrow" style="font-size:14px;">↓</div>
<div class="flow-step" style="border-color:rgba(168,85,247,0.3); font-size:12px;">
<strong style="color:#d8b4fe;">Severity Stratification</strong>
BISAP / Ranson / APACHE II / SIRS criteria
</div>
<div class="flow-arrow" style="font-size:14px;">↓</div>
<div class="flow-step" style="border-color:rgba(34,197,94,0.3); font-size:12px;">
<strong style="color:#86efac;">Triage</strong>
Mild → Ward | Moderate/Severe → HDU/ICU
</div>
</div>
</div>
<div>
<div style="text-align:center; padding:8px; background:rgba(34,197,94,0.15); border-radius:8px; font-size:13px; font-weight:700; color:#86efac; margin-bottom:10px; border:1px solid rgba(34,197,94,0.3);">FIRST 24–48 HOURS</div>
<div class="flow">
<div class="flow-step" style="border-color:rgba(34,197,94,0.3); font-size:12px;">
<strong style="color:#86efac;">IV Fluid Resuscitation</strong>
LR preferred; 250–500 mL/h; UO target ≥0.5 mL/kg/h
</div>
<div class="flow-arrow" style="font-size:14px;">↓</div>
<div class="flow-step" style="border-color:rgba(6,182,212,0.3); font-size:12px;">
<strong style="color:#67e8f9;">Analgesia & Antiemetics</strong>
IV opioids; ondansetron; NGT if severe vomiting
</div>
<div class="flow-arrow" style="font-size:14px;">↓</div>
<div class="flow-step" style="border-color:rgba(234,179,8,0.3); font-size:12px;">
<strong style="color:#fde047;">Nutrition</strong>
Mild: Oral diet ASAP | Severe: EN within 24–48h
</div>
<div class="flow-arrow" style="font-size:14px;">↓</div>
<div class="flow-step" style="border-color:rgba(249,115,22,0.3); font-size:12px;">
<strong style="color:#fdba74;">Etiology Treatment</strong>
Biliary + cholangitis → ERCP <24h | HTG → Insulin/plasmapheresis
</div>
</div>
</div>
<div>
<div style="text-align:center; padding:8px; background:rgba(239,68,68,0.15); border-radius:8px; font-size:13px; font-weight:700; color:#fca5a5; margin-bottom:10px; border:1px solid rgba(239,68,68,0.3);">COMPLICATIONS / FOLLOW-UP</div>
<div class="flow">
<div class="flow-step" style="border-color:rgba(239,68,68,0.3); font-size:12px;">
<strong style="color:#fca5a5;">Identify Necrosis</strong>
CECT at 48–72h if no improvement; gas = infected necrosis
</div>
<div class="flow-arrow" style="font-size:14px;">↓</div>
<div class="flow-step" style="border-color:rgba(168,85,247,0.3); font-size:12px;">
<strong style="color:#d8b4fe;">Infected Necrosis</strong>
Antibiotics → Drainage → VARD/DEN → Open necrosectomy
</div>
<div class="flow-arrow" style="font-size:14px;">↓</div>
<div class="flow-step" style="border-color:rgba(34,197,94,0.3); font-size:12px;">
<strong style="color:#86efac;">Discharge Criteria</strong>
Pain controlled orally, tolerating diet, afebrile, stable
</div>
<div class="flow-arrow" style="font-size:14px;">↓</div>
<div class="flow-step" style="border-color:rgba(59,130,246,0.3); font-size:12px;">
<strong style="color:#93c5fd;">Follow-Up</strong>
Cholecystectomy | DM screen | EPI screen | Recurrence prevention
</div>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 27 — KEY TAKEAWAYS
══════════════════════════════════════════════════ -->
<div class="slide slide-content">
<div class="slide-heading blue">💡 Key Clinical Takeaways</div>
<div style="display:grid; grid-template-columns:1fr 1fr; gap:16px; flex:1;">
<div style="display:flex; flex-direction:column; gap:12px;">
<div class="card green">
<div class="card-title green">Do This ✅</div>
<ul class="styled green">
<li>Use <strong>lipase</strong> (not amylase) as the preferred enzyme marker</li>
<li>Start <strong>IV LR aggressively</strong> within 1–2h of presentation</li>
<li>Begin <strong>enteral nutrition within 24–48h</strong> in moderate-severe AP</li>
<li>Perform <strong>cholecystectomy same admission</strong> in mild biliary AP</li>
<li>Use <strong>rectal indomethacin</strong> to prevent post-ERCP pancreatitis</li>
<li>Delay CECT >72h for best necrosis assessment</li>
<li>Reassess severity at 24h, 48h, 7 days, then weekly</li>
</ul>
</div>
</div>
<div style="display:flex; flex-direction:column; gap:12px;">
<div class="card red">
<div class="card-title red">Avoid This 🚫</div>
<ul class="styled red">
<li>No <strong>prophylactic antibiotics</strong> for sterile necrosis</li>
<li>Avoid routine <strong>ERCP for mild biliary AP</strong> without cholangitis or CBD stone</li>
<li>Do NOT delay feeding to "rest the pancreas" in mild AP</li>
<li>Avoid <strong>over-resuscitation</strong> — leads to abdominal compartment syndrome</li>
<li>Do NOT intervene on asymptomatic sterile necrosis</li>
<li>Avoid normal saline (risk of hyperchloremic acidosis)</li>
</ul>
</div>
<div class="card yellow">
<div class="card-title yellow">2024–2025 Guideline Highlights</div>
<ul class="styled yellow">
<li><strong>IAP/APA 2025:</strong> LR preferred fluid; EN superior to TPN; step-up approach for infected necrosis standard of care</li>
<li><strong>ACG 2024:</strong> Early oral diet safe in mild AP; same-admission cholecystectomy recommended; prophylactic antibiotics not recommended</li>
<li>PMID: <span style="color:#67e8f9;">38857482</span> (ACG 2024) | PMID: <span style="color:#67e8f9;">40651900</span> (IAP 2025)</li>
</ul>
</div>
</div>
</div>
</div>
<!-- ══════════════════════════════════════════════════
SLIDE 28 — REFERENCES
══════════════════════════════════════════════════ -->
<div class="slide slide-content">
<div class="slide-heading blue">📚 References</div>
<div style="flex:1; overflow-y:auto; display:grid; grid-template-columns:1fr 1fr; gap:0 24px;">
<div>
<div class="ref-item"><span>1.</span> Tenner S, Vege SS, et al. "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis." <em>Am J Gastroenterol</em>. 2024. PMID: 38857482</div>
<div class="ref-item"><span>2.</span> IAP/APA/EPC/IPC/JPS Working Group. "International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025." <em>Pancreatology</em>. 2025. PMID: 40651900</div>
<div class="ref-item"><span>3.</span> Banks PA, Bollen TL, et al. "Classification of acute pancreatitis — 2012: revision of the Atlanta classification." <em>Gut</em>. 2013;62:102–111.</div>
<div class="ref-item"><span>4.</span> Goldman-Cecil Medicine, 27th Edition. "Acute Pancreatitis," pp. 1519–1525. ISBN: 9780323930345.</div>
<div class="ref-item"><span>5.</span> Robbins & Kumar Basic Pathology, 10th Edition. "Acute Pancreatitis," pp. 640–644. ISBN: 9780323790185.</div>
<div class="ref-item"><span>6.</span> Current Surgical Therapy, 14th Edition. "Severity Classification and Management of Acute Pancreatitis." ISBN: 9780323796835.</div>
</div>
<div>
<div class="ref-item"><span>7.</span> Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 11th Edition. "Acute Pancreatitis." ISBN: 9780323609623.</div>
<div class="ref-item"><span>8.</span> Mulholland and Greenfield's Surgery, 7th Edition. "Pancreatitis — Step-Up Approach." ISBN: 9781975143169.</div>
<div class="ref-item"><span>9.</span> Grainger & Allison's Diagnostic Radiology. "Imaging in Acute Pancreatitis." ISBN: 9780323760751.</div>
<div class="ref-item"><span>10.</span> Van Santvoort HC, et al. "A step-up approach or open necrosectomy for necrotizing pancreatitis (PANTER Trial)." <em>N Engl J Med</em>. 2010;362:1491–1502.</div>
<div class="ref-item"><span>11.</span> Elmunzer BJ, et al. "A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis." <em>N Engl J Med</em>. 2012;366:1414–1422.</div>
<div class="ref-item"><span>12.</span> Henry's Clinical Diagnosis and Laboratory Methods, 24th Ed. "Laboratory Diagnosis of Pancreatitis." ISBN: 9780323673204.</div>
</div>
</div>
</div>
</div><!-- end slides-wrapper -->
<!-- Navigation -->
<div class="nav">
<button id="prevBtn" onclick="changeSlide(-1)" disabled>← Prev</button>
<span class="slide-counter" id="counter">1 / 28</span>
<button id="nextBtn" onclick="changeSlide(1)">Next →</button>
</div>
<script>
let current = 0;
const slides = document.querySelectorAll('.slide');
const total = slides.length;
document.getElementById('counter').textContent = `1 / ${total}`;
function showSlide(n) {
slides[current].classList.remove('active');
current = Math.max(0, Math.min(n, total - 1));
slides[current].classList.add('active');
document.getElementById('counter').textContent = `${current + 1} / ${total}`;
document.getElementById('prevBtn').disabled = current === 0;
document.getElementById('nextBtn').disabled = current === total - 1;
document.getElementById('progressBar').style.width = `${((current + 1) / total) * 100}%`;
// Scroll active slide's overflow areas to top
slides[current].querySelectorAll('.overflow-auto, [style*="overflow-y:auto"], [style*="overflow-y: auto"]').forEach(el => el.scrollTop = 0);
}
function changeSlide(dir) { showSlide(current + dir); }
document.addEventListener('keydown', e => {
if (e.key === 'ArrowRight' || e.key === 'ArrowDown') changeSlide(1);
else if (e.key === 'ArrowLeft' || e.key === 'ArrowUp') changeSlide(-1);
});
// Touch/swipe support
let touchStartX = 0;
document.addEventListener('touchstart', e => { touchStartX = e.touches[0].clientX; });
document.addEventListener('touchend', e => {
const diff = touchStartX - e.changedTouches[0].clientX;
if (Math.abs(diff) > 50) changeSlide(diff > 0 ? 1 : -1);
});
// Init progress bar
document.getElementById('progressBar').style.width = `${(1 / total) * 100}%`;
</script>
</body>
</html>
Running Command
wc -l /home/daytona/workspace/acute-pancreatitis-ppt/index.html && grep -c 'clas…
Your presentation is ready. Download it here:
index
HTML File · HTML
What's inside — 28 slides across 9 sections
| # | Section | Content |
|---|---|---|
| 1 | Title | Key statistics dashboard (300k admissions, 5% overall mortality, 36–50% severe AP mortality) |
| 2 | Table of Contents | Structured overview of all 12 topic areas |
| 3–4 | Definition & Epidemiology | Revised Atlanta criteria, incidence data, outcomes |
| 5–6 | Etiology | Mechanical / metabolic / drug / genetic / infectious causes with prevalence |
| 7–8 | Pathogenesis | 3 initiating pathways with the Robbins & Kumar pathogenesis diagram embedded |
| 9–10 | Clinical Presentation | Symptoms, signs (Grey Turner / Cullen), DDx, red flags |
| 11–13 | Diagnosis | Lipase vs. amylase, lab panel, CECT criteria, US / MRCP with CT image of necrotizing AP |
| 14–16 | Severity Classification & Scoring | Revised Atlanta 2012 table, BISAP, Ranson's, CTSI (Balthazar), APACHE II |
| 17–18 | Initial Management | LR resuscitation targets, analgesia, triage, etiology-directed interventions |
| 19 | Nutrition & Antibiotics | Early EN mandate, TPN indications, carbapenem regimens, prophylactic antibiotic evidence |
| 20–22 | Complications | APFC / pseudocyst / WON / ANC / systemic, step-up approach (PANTER trial data) |
| 23 | Biliary Pancreatitis | ERCP timing algorithm, cholecystectomy strategy, post-ERCP prophylaxis |
| 24 | Special Scenarios | HTG-induced, pregnancy, autoimmune pancreatitis, recurrent AP, ACS |
| 25 | Discharge & Follow-up | Discharge criteria, DM/EPI screening, recurrence prevention |
| 26 | Management Algorithm | 3-column visual flowchart (admission → 24–48h → complications/follow-up) |
| 27 | Key Takeaways | Do/Avoid checklist + 2024–2025 guideline highlights |
| 28 | References | 12 citations including ACG 2024 (PMID: 38857482) and IAP 2025 (PMID: 40651900) |
Navigation: Arrow keys (← →), on-screen buttons, or swipe on touch devices. A progress bar tracks your position.
This is a shared conversation. Sign in to Orris to start your own chat.